Image Source: AsiaOne
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate GlobeNewswire August 13, 2020 SK bioscience to manufacture antigen component of NVX-CoV2373Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373Novavax, SK bioscience and Republic of Korea intend to partner for manufacture and supply of vaccine for global markets including South KoreaGAITHERSBURG, Md. and SEOUL, South Korea, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for supply to global markets including the COVAX Facility.
Source: AsiaOne